JP2018537501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537501A5 JP2018537501A5 JP2018531479A JP2018531479A JP2018537501A5 JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5 JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound according
- ring
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019843A JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268765P | 2015-12-17 | 2015-12-17 | |
| US62/268,765 | 2015-12-17 | ||
| US201662353603P | 2016-06-23 | 2016-06-23 | |
| US62/353,603 | 2016-06-23 | ||
| PCT/US2016/067112 WO2017106607A1 (en) | 2015-12-17 | 2016-12-16 | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Division JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537501A JP2018537501A (ja) | 2018-12-20 |
| JP2018537501A5 true JP2018537501A5 (enExample) | 2020-01-30 |
| JP6882299B2 JP6882299B2 (ja) | 2021-06-02 |
Family
ID=58191545
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531479A Active JP6882299B2 (ja) | 2015-12-17 | 2016-12-16 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Active JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A Pending JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Active JP7829523B2 (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2025200942A Pending JP2026026116A (ja) | 2015-12-17 | 2025-11-20 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10399957B2 (enExample) |
| EP (3) | EP3889146B1 (enExample) |
| JP (4) | JP6882299B2 (enExample) |
| KR (2) | KR102787063B1 (enExample) |
| CN (2) | CN113603675A (enExample) |
| AU (4) | AU2016371014B2 (enExample) |
| CA (2) | CA3005766A1 (enExample) |
| CL (1) | CL2018001624A1 (enExample) |
| DK (1) | DK3889145T3 (enExample) |
| ES (2) | ES2981114T3 (enExample) |
| FI (1) | FI3889145T3 (enExample) |
| HR (1) | HRP20240355T1 (enExample) |
| HU (1) | HUE066591T2 (enExample) |
| IL (4) | IL259751B (enExample) |
| LT (1) | LT3889145T (enExample) |
| MX (2) | MX2021006804A (enExample) |
| MY (2) | MY196319A (enExample) |
| NZ (1) | NZ742476A (enExample) |
| PH (1) | PH12018501068A1 (enExample) |
| PL (1) | PL3889145T3 (enExample) |
| PT (1) | PT3889145T (enExample) |
| RS (1) | RS65319B1 (enExample) |
| SG (2) | SG10202001146PA (enExample) |
| SI (1) | SI3889145T1 (enExample) |
| SM (1) | SMT202400141T1 (enExample) |
| TW (4) | TWI736566B (enExample) |
| UA (1) | UA124802C2 (enExample) |
| WO (1) | WO2017106607A1 (enExample) |
| ZA (1) | ZA201803367B (enExample) |
Families Citing this family (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| AU2017296392B2 (en) | 2016-07-14 | 2020-09-24 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AU2017311047B2 (en) * | 2016-08-08 | 2021-07-22 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| KR20230010826A (ko) | 2016-10-14 | 2023-01-19 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
| US11370794B2 (en) | 2016-11-11 | 2022-06-28 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| WO2019018354A1 (en) | 2017-07-18 | 2019-01-24 | Merck Patent Gmbh | ANTAGONISTS OF TLR7 / 8 AND USES THEREOF |
| CN111542515B (zh) * | 2017-10-30 | 2023-12-05 | 科罗拉多州立大学董事会法人团体 | Toll样受体8(tlr8)特异性拮抗剂及其制备方法和用途 |
| JP2021506862A (ja) * | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| JP7037667B2 (ja) | 2017-12-20 | 2022-03-16 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド |
| WO2019155042A1 (en) | 2018-02-12 | 2019-08-15 | F. Hoffmann-La Roche Ag | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| US12157746B2 (en) * | 2018-06-05 | 2024-12-03 | Hoffmann-La Roche Inc. | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| JP2021527100A (ja) * | 2018-06-13 | 2021-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 自己免疫疾患の処置のためのピリジニルヘテロシクリル化合物 |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| CN112384505B (zh) * | 2018-07-06 | 2025-05-27 | 吉利德科学公司 | 治疗性的杂环化合物 |
| WO2020017569A1 (ja) * | 2018-07-17 | 2020-01-23 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| SG11202100818RA (en) * | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020043271A1 (en) | 2018-08-28 | 2020-03-05 | F. Hoffmann-La Roche Ag | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease |
| CN112638908A (zh) * | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| EP3847170B1 (en) * | 2018-09-06 | 2022-06-22 | F. Hoffmann-La Roche AG | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020048596A1 (en) | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| EP3847165A1 (en) * | 2018-09-07 | 2021-07-14 | F. Hoffmann-La Roche AG | Novel pyrrolidine amine compounds for the treatment of autoimmune disease |
| WO2020052738A1 (en) * | 2018-09-11 | 2020-03-19 | F. Hoffmann-La Roche Ag | Pyrazolopyridine amine compounds for the treatment of autoimmune disease |
| EP3623369B1 (en) | 2018-09-12 | 2023-10-25 | F. Hoffmann-La Roche AG | Novel morpholinyl amine compounds for the treatment of autoimmune disease |
| CN112752755A (zh) * | 2018-09-27 | 2021-05-04 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的杂环基化合物 |
| EP3873608A1 (en) | 2018-10-31 | 2021-09-08 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| CN109516925B (zh) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | 一种谷氨酸-1-甲酯-5-叔丁酯的合成方法 |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| EP3877388B1 (en) * | 2018-11-09 | 2023-07-26 | F. Hoffmann-La Roche AG | 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus |
| CN109369571A (zh) * | 2018-12-04 | 2019-02-22 | 无锡市赛乐新材料科技有限公司 | 一种含氟取代的7-溴-4-醛基苯并噻二唑及其合成方法 |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US10689360B1 (en) * | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| KR102853071B1 (ko) | 2019-02-07 | 2025-09-02 | 베이진 엘티디 | Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체 |
| CN113574063B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 3’3’-环二核苷酸及其前药 |
| WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| WO2020178769A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| US20220226299A1 (en) * | 2019-03-29 | 2022-07-21 | Nippon Chemiphar Co., Ltd. | Use of t-type calcium channel blocker for treating pruritus |
| US20220340597A1 (en) * | 2019-04-09 | 2022-10-27 | Hoffmann-La Roche Inc. | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| CN112094224B (zh) * | 2019-06-18 | 2022-08-26 | 浙江医药股份有限公司新昌制药厂 | 一种带保护基的3-取代-5-氨基哌啶的制备方法 |
| EP3999509A4 (en) | 2019-07-17 | 2023-07-19 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of somatostatin modulators |
| JP7595643B2 (ja) | 2019-08-02 | 2024-12-06 | ベイジーン リミテッド | Ｔｌｒ８アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| US20220363665A1 (en) * | 2019-09-10 | 2022-11-17 | Hoffmann-La Roche Inc. | Quinoline compounds for the treatment of autoimmune disease |
| US20220395496A1 (en) | 2019-09-16 | 2022-12-15 | Hoffmann-La Roche Inc. | Piperidinyl amine compounds for the treatment of autoimmune disease |
| HRP20241379T1 (hr) | 2019-09-30 | 2024-12-20 | Gilead Sciences, Inc. | Cjepiva za hbv i postupci za liječenje hbv |
| US12590298B2 (en) | 2019-10-18 | 2026-03-31 | The Regents Of The University Of California | Ex vivo tumor angiogenesis model |
| US11884647B2 (en) | 2019-10-18 | 2024-01-30 | The Regents Of The University Of California | Compounds and methods for targeting pathogenic blood vessels |
| CN114599652B (zh) * | 2019-10-31 | 2024-07-12 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡嗪并[1,2-d][1,4]二氮杂䓬化合物 |
| WO2021094301A1 (en) * | 2019-11-12 | 2021-05-20 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| EP4061816A1 (en) | 2019-11-19 | 2022-09-28 | F. Hoffmann-La Roche AG | Hydro-1h-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| US12503471B2 (en) | 2019-11-19 | 2025-12-23 | Hoffmann-La Roche Inc. | Triazatricycle compounds for the treatment of autoimmune disease |
| EP4061821B1 (en) * | 2019-11-20 | 2025-08-06 | F. Hoffmann-La Roche AG | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| US20230041743A1 (en) * | 2019-11-26 | 2023-02-09 | Hoffmann-La Roche Inc. | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |
| US12478621B2 (en) | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| CN114761406B (zh) * | 2019-12-03 | 2024-04-19 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢吡啶并[1,2-a]吡嗪化合物 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| MX2022007671A (es) | 2019-12-18 | 2022-07-19 | Intervet Int Bv | Compuestos antihelminticos que comprenden una estructura de azaindoles. |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| KR102987126B1 (ko) | 2020-03-20 | 2026-07-07 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| US20240024308A1 (en) * | 2020-05-14 | 2024-01-25 | Merck Healthcare Kgaa | Tlr7/8 antagonists for the treatment of coronavirus infections |
| CN116507331A (zh) * | 2020-06-15 | 2023-07-28 | 默克专利有限公司 | Tlr7/8拮抗剂及其用途 |
| WO2022020114A2 (en) | 2020-07-10 | 2022-01-27 | Ting Therapeutics Llc | Methods for the prevention and treatment of hearing loss |
| WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| WO2022028389A1 (zh) * | 2020-08-03 | 2022-02-10 | 江苏恒瑞医药股份有限公司 | 稠三环类衍生物、其制备方法及其在医药上的应用 |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| JP7796115B2 (ja) | 2020-09-09 | 2026-01-08 | クリネティックス ファーマシューティカルズ，インク． | ソマトスタチン調節因子の製剤 |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
| EP4253387A4 (en) | 2020-11-26 | 2024-05-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused tricyclic compound, preparation method therefor and application thereof in medicine |
| KR102513463B1 (ko) * | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| WO2022194237A1 (zh) * | 2021-03-18 | 2022-09-22 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在制备自身免疫药物上的应用 |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN115557968A (zh) * | 2021-07-01 | 2023-01-03 | 江苏恒瑞医药股份有限公司 | 稠四环类化合物、其制备方法及其在医药上的应用 |
| TW202440078A (zh) | 2021-09-10 | 2024-10-16 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| CN115160296B (zh) * | 2022-08-08 | 2024-05-28 | 西安市第五医院 | 一种n-取代喹啉-4-胺类化合物及其制备、药物组合物和应用 |
| CN115650881B (zh) * | 2022-09-06 | 2025-01-17 | 浙江医药股份有限公司新昌制药厂 | 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法 |
| CN120603821A (zh) | 2023-01-18 | 2025-09-05 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025214612A1 (en) | 2023-04-14 | 2025-10-16 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025261608A1 (en) | 2023-06-29 | 2025-12-26 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2026002399A1 (en) | 2023-07-07 | 2026-01-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2026017247A1 (en) | 2023-07-28 | 2026-01-22 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025032197A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile |
| CN121843928A (zh) | 2023-08-09 | 2026-04-10 | 默克专利有限公司 | 5-((3r,55)-3-氨基-5-三氟甲基-哌啶-1-基)-喹啉-8-甲腈盐酸盐的晶型a1 |
| IL326278A (en) | 2023-08-09 | 2026-04-01 | Merck Patent Gmbh | Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| TW202608468A (zh) | 2024-05-13 | 2026-03-01 | 美商基利科學股份有限公司 | 組合療法 |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025252553A1 (en) | 2024-06-04 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025252556A1 (en) | 2024-06-05 | 2025-12-11 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4667451A1 (en) | 2024-06-21 | 2025-12-24 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4691242A1 (en) | 2024-08-06 | 2026-02-11 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4692056A1 (en) | 2024-08-06 | 2026-02-11 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4703353A1 (en) | 2024-09-03 | 2026-03-04 | Syngenta Crop Protection AG | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| EP4745125A1 (en) | 2024-11-18 | 2026-05-20 | Syngenta Crop Protection AG | 2,2-DIHALOCYCLOPROPYL COMPOUNDS ACTIVE AS PESTICIDES |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1020252A (en) * | 1911-04-26 | 1912-03-12 | Arthur H Bell | Brooder. |
| US1016829A (en) * | 1911-05-19 | 1912-02-06 | Abraham Hurwitz | Device for setting pallet-jewels. |
| US1227293A (en) * | 1914-04-10 | 1917-05-22 | Charles H Morison | Safety-catch for cuff-buttons. |
| US1271680A (en) * | 1918-01-15 | 1918-07-09 | Emanuel W Dunn | Heater. |
| US1367747A (en) * | 1919-05-07 | 1921-02-08 | George B Keplinger | Bath-brush |
| DE812911C (de) | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| MXPA04004443A (es) | 2001-11-14 | 2004-08-11 | Merck Patent Gmbh | Derivados de pirazol. |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| NZ538713A (en) | 2002-08-12 | 2007-01-26 | Takeda Chemical Industries Ltd | Fused benzene derivative and use |
| MXPA05005111A (es) | 2002-11-12 | 2005-07-01 | Pfizer Prod Inc | Derivados de quinolina. |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20070225308A1 (en) | 2004-03-15 | 2007-09-27 | Kyowa Hakko Kogyo Co.,Ltd. | 2-Amino Quinazoline Derivative |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| EP1756101A2 (en) | 2004-05-17 | 2007-02-28 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| JP2006056882A (ja) | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物 |
| CN101023083A (zh) * | 2004-07-23 | 2007-08-22 | 田边制药株式会社 | 含氮的稠合双环化合物 |
| EP1772454A4 (en) * | 2004-07-23 | 2009-02-25 | Mitsubishi Tanabe Pharma Corp | NITROGENIC CONDENSED BICYCLIC COMPOUND |
| US20090264415A2 (en) | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| JPWO2007097289A1 (ja) | 2006-02-20 | 2009-07-16 | 武田薬品工業株式会社 | 新規医薬 |
| JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
| EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| US20100004452A1 (en) | 2006-09-26 | 2010-01-07 | Barbara Bertani | 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc. |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| CN101679191B (zh) | 2007-06-05 | 2014-03-12 | 塞诺菲-安万特股份有限公司 | 二杂芳基环己烷衍生物、其制备方法、用途及含有它们的药用组合物 |
| US20110237600A1 (en) | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
| JP5564045B2 (ja) * | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| US8530650B2 (en) * | 2008-12-01 | 2013-09-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| WO2010097410A1 (en) * | 2009-02-24 | 2010-09-02 | Respiratorius Ab | Novel bronchodilating diazaheteroaryls |
| PL2453895T3 (pl) | 2009-07-16 | 2018-10-31 | Mallinckrodt Llc | (+)-morfinany jako antagonisty receptora toll-like 9 i ich zastosowania terapeutyczne |
| US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| EP3483167A1 (en) | 2013-06-26 | 2019-05-15 | AbbVie Inc. | Primary carboxamides as btk inhibitors |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| ES3069593T3 (en) | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| ES2670550T3 (es) * | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| KR101823488B1 (ko) | 2013-10-14 | 2018-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| US9643967B2 (en) | 2013-12-13 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors |
| EP3083618B1 (en) | 2013-12-17 | 2018-02-21 | Pfizer Inc | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| WO2015120111A2 (en) | 2014-02-05 | 2015-08-13 | Stereokem, Inc. (Usa) | Expedient synthesis of sitagliptin |
| JP6377245B2 (ja) | 2014-03-24 | 2018-08-22 | グアンドン ジョンシェン ファーマシューティカル カンパニー リミテッド | Ｓｍｏ阻害剤としてのキノリン誘導体 |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| ES2804101T3 (es) | 2014-04-22 | 2021-02-03 | Hoffmann La Roche | Compuestos de 4-amino-imidazoquinolina |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| CN107108556B (zh) | 2014-11-03 | 2020-09-29 | 艾欧米制药有限公司 | 药用化合物 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| CN108290855A (zh) | 2015-07-01 | 2018-07-17 | 西北大学 | 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途 |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| AU2017311047B2 (en) | 2016-08-08 | 2021-07-22 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| WO2019018354A1 (en) | 2017-07-18 | 2019-01-24 | Merck Patent Gmbh | ANTAGONISTS OF TLR7 / 8 AND USES THEREOF |
| JP2021506862A (ja) | 2017-12-19 | 2021-02-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｔｌｒ７／８アンタゴニストおよびそれらの使用 |
| SG11202100818RA (en) * | 2018-07-31 | 2021-02-25 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
-
2016
- 2016-12-16 MX MX2021006804A patent/MX2021006804A/es unknown
- 2016-12-16 EP EP21172998.3A patent/EP3889146B1/en active Active
- 2016-12-16 PT PT211729967T patent/PT3889145T/pt unknown
- 2016-12-16 LT LTEP21172996.7T patent/LT3889145T/lt unknown
- 2016-12-16 JP JP2018531479A patent/JP6882299B2/ja active Active
- 2016-12-16 ES ES21172996T patent/ES2981114T3/es active Active
- 2016-12-16 NZ NZ742476A patent/NZ742476A/en unknown
- 2016-12-16 CA CA3005766A patent/CA3005766A1/en active Pending
- 2016-12-16 EP EP21172996.7A patent/EP3889145B1/en active Active
- 2016-12-16 DK DK21172996.7T patent/DK3889145T3/da active
- 2016-12-16 UA UAA201807881A patent/UA124802C2/uk unknown
- 2016-12-16 CN CN202110952016.2A patent/CN113603675A/zh active Pending
- 2016-12-16 SI SI201631813T patent/SI3889145T1/sl unknown
- 2016-12-16 MX MX2018006637A patent/MX385424B/es unknown
- 2016-12-16 SG SG10202001146PA patent/SG10202001146PA/en unknown
- 2016-12-16 CA CA3314120A patent/CA3314120A1/en active Pending
- 2016-12-16 MY MYPI2018702111A patent/MY196319A/en unknown
- 2016-12-16 MY MYPI2023001174A patent/MY210123A/en unknown
- 2016-12-16 HR HRP20240355TT patent/HRP20240355T1/hr unknown
- 2016-12-16 CN CN201680081793.1A patent/CN108699032B/zh active Active
- 2016-12-16 HU HUE21172996A patent/HUE066591T2/hu unknown
- 2016-12-16 SM SM20240141T patent/SMT202400141T1/it unknown
- 2016-12-16 SG SG11201804170RA patent/SG11201804170RA/en unknown
- 2016-12-16 ES ES16840344T patent/ES2883285T3/es active Active
- 2016-12-16 PL PL21172996.7T patent/PL3889145T3/pl unknown
- 2016-12-16 EP EP16840344.2A patent/EP3390389B1/en active Active
- 2016-12-16 KR KR1020187018717A patent/KR102787063B1/ko active Active
- 2016-12-16 AU AU2016371014A patent/AU2016371014B2/en active Active
- 2016-12-16 FI FIEP21172996.7T patent/FI3889145T3/fi active
- 2016-12-16 RS RS20240342A patent/RS65319B1/sr unknown
- 2016-12-16 KR KR1020257009400A patent/KR20250043596A/ko active Pending
- 2016-12-16 US US15/381,406 patent/US10399957B2/en active Active
- 2016-12-16 WO PCT/US2016/067112 patent/WO2017106607A1/en not_active Ceased
- 2016-12-19 TW TW105142060A patent/TWI736566B/zh active
- 2016-12-19 TW TW114116751A patent/TW202547833A/zh unknown
- 2016-12-19 TW TW112116054A patent/TWI886474B/zh active
- 2016-12-19 TW TW110137731A patent/TWI804003B/zh active
-
2018
- 2018-05-17 PH PH12018501068A patent/PH12018501068A1/en unknown
- 2018-05-21 ZA ZA2018/03367A patent/ZA201803367B/en unknown
- 2018-05-31 IL IL259751A patent/IL259751B/en active IP Right Grant
- 2018-05-31 IL IL279751A patent/IL279751B/en active IP Right Grant
- 2018-06-15 CL CL2018001624A patent/CL2018001624A1/es unknown
-
2019
- 2019-07-10 US US16/507,870 patent/US10544122B2/en active Active
- 2019-11-26 US US16/696,503 patent/US10696649B2/en active Active
-
2020
- 2020-04-28 US US15/929,348 patent/US10947213B1/en active Active
- 2020-12-19 US US17/128,021 patent/US11629134B2/en active Active
- 2020-12-24 IL IL279752A patent/IL279752B2/en unknown
- 2020-12-24 IL IL279751A patent/IL279751A/en active IP Right Grant
-
2021
- 2021-02-10 JP JP2021019843A patent/JP7317878B2/ja active Active
- 2021-08-17 AU AU2021218041A patent/AU2021218041B2/en active Active
-
2023
- 2023-03-06 US US18/179,211 patent/US20230303514A1/en not_active Abandoned
- 2023-07-19 JP JP2023117597A patent/JP7829523B2/ja active Active
- 2023-12-18 AU AU2023285714A patent/AU2023285714A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/923,917 patent/US20250059157A1/en active Pending
-
2025
- 2025-11-20 JP JP2025200942A patent/JP2026026116A/ja active Pending
- 2025-11-28 AU AU2025271466A patent/AU2025271466A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536369A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| JP2020537671A5 (enExample) | ||
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| JP2021533125A5 (enExample) | ||
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2017524733A5 (enExample) | ||
| FI3788044T3 (fi) | RIP1:tä estäviä yhdisteitä ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| JP2017530959A5 (enExample) | ||
| JP2015518903A5 (enExample) | ||
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| JP2022515406A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2017506675A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| JP2020517611A5 (enExample) | ||
| JP2015514060A5 (enExample) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2014533281A5 (enExample) | ||
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2017514910A5 (enExample) | ||
| JP2017509689A5 (enExample) |